A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Beckman Symposium Bookmark and Share

The 24th Beckman Symposium - New Horizons on Oncogenesis

Date
Friday, November 14, 2014
8:45 a.m. to 5:30 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 24th Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2014 Speaker List:
 
Joe Gray, Ph.D.,
Knight Cancer Institute, University of Oregon Health and Science University
 
Edward T.H. Yeh, M.D.,
University of Texas MD Anderson Cancer Center
 
Iannis Aifantis, Ph.D.,
Howard Hughes Medical Institute and NYU School of Medicine
 
Valerie Weaver, Ph.D.,
University of California, San Francisco
 
Channing Der, Ph.D.,
Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
Dafna Bar-Sagi, Ph.D.,
NYU Langone Medical Center
 
David Cheresh, Ph.D.,
Moores Cancer Center, University of California,  San Diego

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

2014 Symposium Program

8:15 to 8:45 a.m.
Registration
 
8:50 to 9:00 a.m.
Welcome, Steven Rosen, M.D., Provost, City of Hope
 
9:00 to 10:00 a.m.
Spatial Systems Biology of Cancer
Joe Gray, Ph.D., Knight Cancer Institute, University of Oregon Health and Science University
 
10:00 to 10:15 a.m.
Break
 
10:15 to 11:15 a.m.
Doxorubicin-induced Cardiotoxicity: SUMO, Ubiquitin, and Topoisomerase 2b
Edward T.H. Yeh, M.D., University of Texas MD Anderson Cancer Center
 
11:15 a.m. to 12:15 p.m.
Epigenetic Regulation of Acute Leukemia Initiation and Progression Iannis Aifantis, Ph.D., Howard Hughes Medical Institute and NYU School of Medicine
 
12:15 to 1:15 p.m.
Lunch
 
1:15 to 2:15 p.m.
Tissue Force, Tumor Progression and Treatment
Valerie Weaver, Ph.D., University of California, San Francisco
 
2:15 to 3:15 p.m.
Drugging the Undruggable Ras: Mission Possible?
Channing Der, Ph.D., Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
3:15 to 3:30 p.m.
Break
 
3:30 to 4:30 p.m.
Oncogenic Ras Signaling: From Biology to Therapeutics
Dafna Bar-Sagi, Ph.D., NYU Langone Medical Center
 
4:30 to 5:30 p.m.
A β3 Integrin-KRAS-RalB Complex Drives Tumor Stemness and Resistance to EGFR Inhibition
David Cheresh, Ph.D., Moores Cancer Center, University of California,  San Diego

Beckman Symposium

The 24th Beckman Symposium - New Horizons on Oncogenesis

Date
Friday, November 14, 2014
8:45 a.m. to 5:30 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 24th Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2014 Speaker List:
 
Joe Gray, Ph.D.,
Knight Cancer Institute, University of Oregon Health and Science University
 
Edward T.H. Yeh, M.D.,
University of Texas MD Anderson Cancer Center
 
Iannis Aifantis, Ph.D.,
Howard Hughes Medical Institute and NYU School of Medicine
 
Valerie Weaver, Ph.D.,
University of California, San Francisco
 
Channing Der, Ph.D.,
Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
Dafna Bar-Sagi, Ph.D.,
NYU Langone Medical Center
 
David Cheresh, Ph.D.,
Moores Cancer Center, University of California,  San Diego

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

Symposium Program

2014 Symposium Program

8:15 to 8:45 a.m.
Registration
 
8:50 to 9:00 a.m.
Welcome, Steven Rosen, M.D., Provost, City of Hope
 
9:00 to 10:00 a.m.
Spatial Systems Biology of Cancer
Joe Gray, Ph.D., Knight Cancer Institute, University of Oregon Health and Science University
 
10:00 to 10:15 a.m.
Break
 
10:15 to 11:15 a.m.
Doxorubicin-induced Cardiotoxicity: SUMO, Ubiquitin, and Topoisomerase 2b
Edward T.H. Yeh, M.D., University of Texas MD Anderson Cancer Center
 
11:15 a.m. to 12:15 p.m.
Epigenetic Regulation of Acute Leukemia Initiation and Progression Iannis Aifantis, Ph.D., Howard Hughes Medical Institute and NYU School of Medicine
 
12:15 to 1:15 p.m.
Lunch
 
1:15 to 2:15 p.m.
Tissue Force, Tumor Progression and Treatment
Valerie Weaver, Ph.D., University of California, San Francisco
 
2:15 to 3:15 p.m.
Drugging the Undruggable Ras: Mission Possible?
Channing Der, Ph.D., Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
3:15 to 3:30 p.m.
Break
 
3:30 to 4:30 p.m.
Oncogenic Ras Signaling: From Biology to Therapeutics
Dafna Bar-Sagi, Ph.D., NYU Langone Medical Center
 
4:30 to 5:30 p.m.
A β3 Integrin-KRAS-RalB Complex Drives Tumor Stemness and Resistance to EGFR Inhibition
David Cheresh, Ph.D., Moores Cancer Center, University of California,  San Diego
Research Overview
Research pioneered at City of Hope has improved the lives of men, women and children throughout the world.
 
Beckman Research Institute

Beckman Research Institute of City of Hope is internationally  recognized for its innovative translational biomedical research.
 

Comprehensive Cancer Center
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and education.

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Technology & Licensing
The Center for Applied Technology Development offers broad expertise in
technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 



NEWS & UPDATES
  • Patients undergoing treatment at City of Hope know they will be receiving the best medical care available, that their treatment will be delivered with compassion and that their care will extend to their families. “When we treat a patient here, we treat a family,” says Jo Ann S. Namm, child life manager and spec...
  • Did you know that colorectal cancer equally affects men and women? Or that it’s the third-leading cause of cancer death in the U.S.? Most important, did you know that colorectal cancer is very treatable and highly curable if detected early? If you didn’t know these facts, it’s time to learn. M...
  • To celebrate the beginning of Lunar New  Year 2015, City of Hope honored not just a new lunar calendar, but also the diversity of the community it serves. On Jan. 21, as tens of thousands of people celebrated Lunar New Year (and the arrival of the Year of the Ram) in the streets of L.A.’s Chinatown, City of [&#...
  • The breakthroughs that have revolutionized cancer treatment, transforming cancer in many cases to a very manageable and even curable disease, started out as just ideas. “I will often tell patients there’s no therapy we’re using to help them that wasn’t derived from somebody’s idea in some laboratory, working la...
  • The prostate cancer screening debate, at least as it relates to regular assessment of prostate specific antigen levels, is far from over. The U.S. Preventive Services Task Force recommended against routine PSA screening for prostate cancer in 2012, maintaining that the routine use of the PSA blood test does mor...
  • Cancer patients should get more than medical treatment. They should get comprehensive, evidence-based care that addresses their full range of needs. That kind of patient-focused care is City of Hope’s specialty. Under the guidance of Dawn Gross, M.D., Ph.D., the new Arthur M. Coppola Family Chair in Suppo...
  • Think twice before tossing out those hormone replacement pills. Although a new Lancet study suggests that hormone replacement therapy could increase a woman’s risk of ovarian cancer, a City of Hope expert urges women to keep this news in perspective. Hormone replacement therapy is prescribed to help allev...
  • Don’t know what to take, or send, that friend of yours in the hospital? Try a paper plate — filled not with cookies or sweets, but an image of yourself. Ilana Massi, currently undergoing treatment at City of Hope for acute myeloid leukemia, can vouch for the power of such a gift. She’s surrounded herself [̷...
  • With precision medicine now a national priority, City of Hope has joined a novel research partnership designed to further understanding of cancer at the molecular level, ultimately leading to more targeted cancer treatments. The Oncology Research Information Exchange Network, or ORIEN, is the world’s larg...
  • The spinal cord is an integral part of the human body, connecting the brain to everything else. So when a tumor grows on the spine, any messages that the brain tries to send to the rest of the body are interrupted, making everyday tasks — such as walking — more difficult. This year an estimated 22,850 […]
  • Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor’s stem cells), offering them a chance at cure. Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 perc...
  • Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, offers his perspective on the benefits of surgery for aggressive prostate cancer. For men walking out of the doctor’s office after a diagnosis of cancer, the reality can hit like a ton of bricks. Th...
  • Although many Hispanic women face a high risk of mutations in the BRCA1 and BRCA2 genes – increasing their risk of breast and ovarian cancer – screenings for these mutations can be prohibitively expensive in Mexico and other Latin American countries. As a result, too many women don’t get the information t...
  • Providing lung cancer treatments to patients when their cancer is at its earliest and most treatable stages will now be a more attainable goal: Medicare has agreed to cover lung cancer screening for those beneficiaries who meet the requirements. The only proven way to detect lung cancer early enough to save liv...
  • At City of Hope, innovative scientific research, important clinical studies and vital construction projects are all powered by philanthropy. Generous supporters fuel a powerful and diverse range of progress in science and medicine, enabling researchers and clinicians to improve cancer treatments and create cure...